Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Much Larger Is The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Expected To Become By 2029 Compared With Its 2025 Level?
The market for glucagon-like peptide (glp)-1 agonists weight loss drugs has experienced rapid expansion in recent years. It is projected to increase from $13.38 billion in 2024 to $15.5 billion in 2025, showing a compound annual growth rate (CAGR) of 15.9%. Historically, this growth can be attributed to the rising incidence of obesity, an increase in type 2 diabetes cases, heightened awareness of obesity-related health risks, growing healthcare expenditure, a stronger focus on chronic disease management, and enhanced access to healthcare.
The market for glucagon-like peptide (GLP)-1 agonists in weight loss pharmaceuticals is projected to experience swift expansion in the upcoming period. This sector is set to reach a valuation of $28.3 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 16.3%. Factors contributing to this anticipated growth during the forecast period include a heightened demand for efficacious weight management options, the broadening of drug applications beyond diabetes treatment, increased capital expenditure in research and development, the expanding acceptance of tailored medical approaches, and enhanced public knowledge fostered by direct-to-consumer promotional efforts. Key developments expected in this period encompass the creation of oral glucagon-like peptide (GLP)-1 formulations, improvements in sustained-release medication delivery systems, the incorporation of digital health instruments for observation, the application of artificial intelligence in identifying and developing new drugs, and breakthroughs in peptide engineering aimed at boosting effectiveness.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24226&type=smp
What Are The Emerging Market Drivers Creating New Opportunities In The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Industry?
The increasing occurrence of obesity is anticipated to stimulate the expansion of the glucagon-like peptide (GLP)-1 agonist weight loss drugs market in the future. Obesity is defined as a medical state marked by an excessive build-up of body fat, posing health risks. The rates of obesity are climbing, attributed to poor dietary practices involving higher consumption of fast food and sugary beverages, alongside an absence of adequate nutrition and balance. With a continuous increase in individuals suffering from obesity and associated complications, there’s a growing need for effective treatments. This in turn boosts the adoption of glucagon-like peptide (GLP)-1 agonist weight loss drugs, known for their demonstrated capability to aid weight loss and improve metabolic health. For example, data from March 2024, sourced from the World Health Organization, a Switzerland-based intergovernmental body, indicated that in 2022, one in eight individuals worldwide lived with obesity. Out of 2.5 billion overweight adults, around 890 million were identified as obese. Furthermore, globally, 43% of the adult population was overweight, and 16% were considered obese. Consequently, the escalating prevalence of obesity is fueling the expansion of the glucagon-like peptide (GLP)-1 agonist weight loss drugs market.
What Are The Segment Types Shaping The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
The glucagon-like peptide (glp)-1 agonists weight loss drugsmarket covered in this report is segmented –
1) By Drugs: Semaglutide; Liraglutide; Tirzepatide; Other Drugs
2) By Route of Administration: Parenteral; Oral
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Pharmacies
Subsegments:
1) By Semaglutide: Ozempic; Wegovy; Rybelsus
2) By Liraglutide: Saxenda; Victoza
3) By Tirzepatide: Mounjaro; Zepbound
4) By Other Drugs: Exenatide; Dulaglutide; Albiglutide; Efpeglenatide
What Are The Major Trends Driving The Growth Of The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
Leading companies within the glucagon-like peptide (GLP)-1 agonist weight loss drugs market are developing innovative solutions for obesity treatment to boost efficacy and improve patient outcomes. These obesity treatment solutions are therapies designed to mimic the GLP-1 hormone, thereby regulating appetite, increasing satiety, and encouraging weight loss. Such medications assist in managing obesity by enhancing metabolic function and supporting long-term weight control. For instance, in November 2023, Eli Lilly and Company, a US-based pharmaceutical firm, received US Food and Drug Administration approval for Zepbound, a medication for chronic weight management in adults with obesity or who are overweight with related health conditions such as type 2 diabetes or sleep apnea. The drug functions by activating GIP and GLP-1 hormone receptors to suppress appetite and enhance metabolic function.
Which Leading Players Are Enhancing Their Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Presence Worldwide?
Major companies operating in the glucagon-like peptide (GLP)-1 agonists weight loss drugs market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc, Amgen Inc., Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim, Jiangsu Hengrui Medicine Co. Ltd, BioAge Labs, Hanmi Pharmaceutical, Innovent Biologics Inc., Viking Therapeutics Inc., Structure Therapeutics Inc., Zealand Pharma A/S, Regor Therapeutics Inc., I-Mab Biopharma (Shanghai) Co. Ltd., Altimmune Inc., TheracosBio LLC., Oramed Pharmaceuticals.
Download The Full Report For Exclusive Market Findings:
Which Region Is Expected To Witness The Fastest Growth In The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
North America was the largest region in the glucagon-like peptide (GLP) -1 agonists weight loss drugs market in 2024. The regions covered in the glucagon-like peptide (GLP)-1 agonists weight loss drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report:
https://www.thebusinessresearchcompany.com/customise?id=24226&type=smp
Browse Through More Reports Similar to the Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market 2025, By The Business Research Company
Pharmaceutical Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-global-market-report
Oral Biologics And Biosimilar Drug Global Market Report 2025
Anti Asthmatics And Copd Drugs Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model